Back to today’s briefing

Story perspectives

Genetic Testing Cuts Chemo Side Effects by 27%

8/10/2025

46 5

Summary

Story summary

A groundbreaking study from the University of Pennsylvania reveals that pharmacogenetic testing for DPYD and UGT1A1 gene variants can dramatically lower severe side effects in gastrointestinal cancer patients receiving chemotherapy. By customizing doses based on genetic profiles, adverse events plummeted from 65% to 38%, highlighting the urgent need for widespread adoption of genetic testing in cancer treatment.

1 of 1

Story summary

A groundbreaking study from the University of Pennsylvania reveals that pharmacogenetic testing for DPYD and UGT1A1 gene variants can dramatically lower severe side effects in gastrointestinal cancer patients receiving chemotherapy. By customizing doses based on genetic profiles, adverse events plummeted from 65% to 38%, highlighting the urgent need for widespread adoption of genetic testing in cancer treatment.